The Effect Of Acadesine On Clinically Significant Adverse Cardiovascular and Cerebrovascular Events In High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (Protocol No. P05633): RED-CABG Trial (Reduction in Cardiovascular Events by AcaDesine in Subjects Undergoing CABG).

Trial Profile

The Effect Of Acadesine On Clinically Significant Adverse Cardiovascular and Cerebrovascular Events In High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (Protocol No. P05633): RED-CABG Trial (Reduction in Cardiovascular Events by AcaDesine in Subjects Undergoing CABG).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2012

At a glance

  • Drugs Acadesine (Primary)
  • Indications Cardiovascular disorders; Cerebrovascular disorders; Coronary disorders; Embolism and thrombosis
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms RED-CABG
  • Sponsors Merck & Co; Schering-Plough
  • Most Recent Events

    • 21 Oct 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 04 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 04 Aug 2010 Planned end date changed from 1 Oct 2010 to 1 Apr 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top